NYSE:ADCT - Get Free Report ) posted its quarterly earnings results on Monday. The company reported ($0.56) EPS for the quarter, hitting analysts' consensus estimates of ($0.56), Yahoo Finance reports. ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. The company had revenue of $18.05 million during the quarter, compared to analysts' expectations of $18.19 million. During the same quarter in the previous year, the firm earned ($0.74) EPS.
Get ADC Therapeutics alerts:
Sign Up
ADC Therapeutics Stock Up 8.5 % Shares of NYSE ADCT traded up $0.38 during trading on Tuesday, reaching $4.83. The company had a trading volume of 885,662 shares, compared to its average volume of 747,439. The company's fifty day moving average price is $4.58 and its 200-day moving average price is $2.87. ADC Therapeutics has a 12 month low of $0.36 and a 12 month high of $6.04. The stock has a market cap of $399.97 million, a P/E ratio of -1.65 and a beta of 1.69.
Analysts Set New Price Targets A number of equities research analysts recently weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $8.00 price objective on shares of ADC Therapeutics in a research report on Thursday, March 14th. Guggenheim restated a "buy" rating on shares of ADC Therapeutics in a research report on Friday, April 5th. Finally, HC Wainwright reduced their price objective on ADC Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $7.25.
View Our Latest Stock Report on ADCT
About ADC Therapeutics (
Get Free Report )
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Featured Articles
Before you consider ADC Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.
While ADC Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
